Xu-Dong Yang

PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia.

M. Minden, Zhu Chen, Yanzhi Du, 2010, Cancer cell.

Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial

Yong-bin Ding, Xiao-Feng Chen, Guo-Qun Wang, 2021, OncoTargets and therapy.